Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

Robert J. Motzer,Scott S. Tykodi,Bernard Escudier,Stéphane Oudard,Hans J. Hammers,David F. McDermott,Saby George,Daniel Castellano,Toni K. Choueiri,Ajjai Alva,Martin Eduardo Richardet,Elizabeth R. Plimack,Sandy Srinivas,Giuseppe Procopio,Frede Donskov,Howard Gurney,Yoshihiko Tomita,M. Brent McHenry,Shruti Shally Saggi,Nizar M. Tannir

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

2020

617Background: CheckMate 025 demonstrated superior overall survival (OS) in previously treated patients (pts) with aRCC, with improved safety and tolerability in the NIVO arm compared with EVE. The...

Keywords:

Oncology
Nivolumab
Pathology
Internal medicine
Checkmate
Renal cell carcinoma
Tolerability
Everolimus
Medicine
overall survival
in patient
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations